Group 1 - Connect Biopharma Holdings Limited is a U.S.-headquartered global clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases through T cell-driven research [1][2] - The company is hosting one-on-one investor meetings at the Leerink Partners Inflammation and Immunology and Metabolism Therapeutics Forum on July 9-10, 2024, in Boston, MA [1] - Connect Biopharma is developing a pipeline of proprietary small molecules and antibodies, with its lead product candidate rademikibart targeting interleukin-4 receptor alpha for atopic dermatitis and asthma [2] Group 2 - The second product candidate, icanbelimod, is a modulator of S1P1 T cell receptors in development for ulcerative colitis [2] - The company's goal is to improve the lives of millions affected by chronic inflammatory diseases worldwide [2]
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum